Back to Search Start Over

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

Authors :
Ossenkoppele, G. J.
Breems, D. A.
Stuessi, G.
van Norden, Y.
Bargetzi, M.
Biemond, B. J.
A von dem Borne, P.
Chalandon, Y.
Cloos, J.
Deeren, D.
Fehr, M.
Gjertsen, B. T.
Graux, C.
Huls, G.
Janssen, J. J.J.W.
Jaspers, A.
Jongen-Lavrencic, M.
de Jongh, E.
Klein, S. K.
Van der Klift, M.
Van Marwijk Kooy, M.
Maertens, J.
Michaux, L.
van der Poel, M. W.M.
Van Rhenen, A.
Tick, L.
Valk, P.
Vekemans, M. C.
van der Velden, W. J.F.M.
de Weerdt, O.
Pabst, T.
Manz, M.
Löwenberg, B.
Havelange
Moors, I.
van Obberg, F.
Maertens, J. A.
Hodossy, B.
Vansteenweghen, S.
Lammertijn, L.
Sonet, A.
Triffet, A.
Passweg, J.
Heim, D.
Giovanni, San
Stuessi, Georg
Betticher, D.
Spertini, O.
Gregor, M.
Hess, U.
Manz, M. G.
van de Loosdrecht, A.
Janssen, J. J.W.M.
van Esser, J. W.J.
Brouwer, R. E.
Van Lammeren-Venema, D.
Levin, M. D.
Tick, L. W.
Legdeur, M. C.J.C.
Vellenga, E.
Hoogendoorn, M.
Veelken, J. H.
von dem Borne, P. A.
Schouten, H. C.
Cornelissen, J.
Wouters, B.
Raaijmakers, H. G.M.
Kuball, J.
Hematology laboratory
CCA - Cancer Treatment and quality of life
Hematology
Source :
Leukemia, 34(10). Nature Publishing Group, Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
Publication Year :
2020

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Details

Language :
English
ISSN :
08876924
Database :
OpenAIRE
Journal :
Leukemia, 34(10). Nature Publishing Group, Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
Accession number :
edsair.dedup.wf.001..4231d8d48f8da424335ae95804aeb6bc
Full Text :
https://doi.org/10.1038/s41375-020-0725-0)